Trials / Completed
CompletedNCT04417348
Opsin Receptors in Melasma
Expression of Opsins Receptors in Melasma and Its Modification With UV-Visible Light Sunscreen and 0.05% Retinoic Acid.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Universidad Autonoma de San Luis Potosí · Academic / Other
- Sex
- Female
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
Melasma is a hyperpigmentation disorder that is probably exacerbated by visible light. Opsin receptors (OPN 1, 2, 3, 4 y 5) were described in the skin, being capable of activating melanogenesis induced by visible light. The aim of this study was to evaluate the expression of OPN in melasma skin and its changes following treatment with UV-Vis filter and 0.05% retinoic acid for 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Retinoic acid | To evaluate the role of Opsin receptors in melasma. The patients were treated with 0.05% Retinoic Acid, a regular therapy to treatment melasma, a ligand of Opsin receptors. Also, Uv-Visible light filter treatment as a posible opsin receptor blocker |
Timeline
- Start date
- 2019-01-31
- Primary completion
- 2019-09-30
- Completion
- 2019-12-15
- First posted
- 2020-06-04
- Last updated
- 2020-06-04
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT04417348. Inclusion in this directory is not an endorsement.